Free Trial

Novo Nordisk A/S (NYSE:NVO) Shares Up 1.6% - Should You Buy?

Novo Nordisk A/S logo with Medical background

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s share price shot up 1.6% during trading on Tuesday . The stock traded as high as $70.60 and last traded at $70.43. 2,537,071 shares were traded during trading, a decline of 65% from the average session volume of 7,245,082 shares. The stock had previously closed at $69.32.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NVO. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $112.00.

View Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Price Performance

The company has a market capitalization of $310.90 billion, a PE ratio of 20.60, a PEG ratio of 1.35 and a beta of 0.64. The firm has a fifty day moving average of $70.19 and a two-hundred day moving average of $75.37. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion during the quarter. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently bought and sold shares of the business. Range Financial Group LLC lifted its holdings in Novo Nordisk A/S by 3.1% in the 2nd quarter. Range Financial Group LLC now owns 11,491 shares of the company's stock worth $793,000 after buying an additional 350 shares during the period. Atwood & Palmer Inc. lifted its holdings in Novo Nordisk A/S by 31.8% in the 2nd quarter. Atwood & Palmer Inc. now owns 737 shares of the company's stock worth $51,000 after buying an additional 178 shares during the period. Atlas Brown Inc. raised its position in shares of Novo Nordisk A/S by 11.5% in the 2nd quarter. Atlas Brown Inc. now owns 9,025 shares of the company's stock worth $623,000 after acquiring an additional 933 shares in the last quarter. Martin Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 261.5% in the 2nd quarter. Martin Capital Partners LLC now owns 76,448 shares of the company's stock worth $5,276,000 after acquiring an additional 55,298 shares in the last quarter. Finally, Canandaigua National Bank & Trust Co. raised its position in shares of Novo Nordisk A/S by 42.0% in the 2nd quarter. Canandaigua National Bank & Trust Co. now owns 6,068 shares of the company's stock worth $419,000 after acquiring an additional 1,795 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Articles

Should You Invest $1,000 in Novo Nordisk A/S Right Now?

Before you consider Novo Nordisk A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.

While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines